Europe
BioIVT will help to generate drug discovery target validation data and characterize novel therapeutics
As more gene therapies advance to clinical trials, participants will discuss which are the best strategies for manufacturing to scale
Eisai Co., Ltd. announced that a series of abstracts will be presented during the European Society for Medical Oncology 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019.
The procedures were performed at Rouen University Hospital and Clinique Pasteur in Toulouse (France) and precede the first clinical study of its kind to be conducted in Europe
SkylineDx announced at the 32nd Biennial Dermatology Symposium: The O’Leary Meeting 2019 in Rochester the launch of a pilot study it will conduct with the Mayo Clinic to evaluate and optimize its diagnostic services focused on primary cutaneous melanoma.
Summit Therapeutics plc and collaborators will present new data analyses from the Phase 2 clinical trial of ridinilazole in patients with C. difficile infection (‘CDI’) at ID Week 2019, taking place 2-6 October 2019 in Washington, DC.
Apogenix, a biopharmaceutical company developing next generation immuno-oncology therapeutics, announced that it will be supporting a colloquium titled “Recurrent Glioblastoma Management: Challenges and Opportunities” at this year’s ESMO Congress, held from September 27 to October 1 at the Fira Gran Via in Barcelona, Spain.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.
Artios Pharma Limited announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States.
Silence Therapeutics, PLC announces the triggering of the first $2 million in research milestones for SLN500 under the collaboration with Mallinckrodt Pharmaceuticals, a global biopharmaceutical company.
PRESS RELEASES